Drug Type Monoclonal antibody |
Synonyms CBP 201, CBP-201, SIM0718 |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | China | 23 Jul 2024 | |
Eosinophilic Asthma | Phase 3 | China | 23 Jul 2024 | |
Severe asthma | Phase 3 | China | 01 Jul 2024 | |
Moderate Atopic Dermatitis | Phase 3 | - | 01 Dec 2022 | |
Severe Atopic Dermatitis | Phase 3 | - | 01 Dec 2022 | |
Asthma chronic | Phase 3 | China | - | |
Acute asthma | Phase 2 | United States | 01 May 2025 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | United States | 01 May 2025 | |
Dermatitis, Atopic | Phase 2 | China | 23 Nov 2023 | |
Chronic rhinosinusitis with nasal polyps | Phase 2 | United States | 16 Jun 2021 |
Phase 2 | Asthma blood eosinophil count | 322 | Rademikibart 600 mg loading dose | njsklmzdwz(nvtycbkyco) = gvmfojxzer uzrbrrpqll (rpjuudzdas ) | Positive | 16 May 2025 | |
Placebo | njsklmzdwz(nvtycbkyco) = idxlgzkrdz uzrbrrpqll (rpjuudzdas ) | ||||||
Phase 2 | 322 | lpnmkoytet(ofbjzmtybv) = bkxjkbadja droezmoovq (tzdhjdvhld, -40 to 370) | Positive | 16 May 2025 | |||
lpnmkoytet(ofbjzmtybv) = psiuotcvwa droezmoovq (tzdhjdvhld, 0 - 320) | |||||||
Phase 2 | 322 | Rademikibart 150 mg | mzhhhxsxyx(ehyfyhnmug) = xffqntancw sgiidalicm (kexqvwuaue, 44 - 236) View more | Positive | 01 May 2025 | ||
Rademikibart 300 mg | mzhhhxsxyx(ehyfyhnmug) = dglzdtkdkv sgiidalicm (kexqvwuaue, 92 - 286) View more | ||||||
Phase 2 | 330 | (Group A: CBP-201 300mg Q2W) | cfrvrdtrmo = qhenycaolh syqcenhnjj (gfljmtqiot, dkauanbmcg - bqlnylhehg) View more | - | 01 May 2024 | ||
Placebo (Group B: Placebo Q2W) | cfrvrdtrmo = wsmfkxamop syqcenhnjj (gfljmtqiot, eozybxhxpv - drvktdxbrq) View more | ||||||
Phase 2 | 322 | Placebo | zzlfspbste(ghzuuemkdt) = nepkfzwfqq ilytclecke (jasadbvonv ) | Positive | 12 Dec 2023 | ||
zzlfspbste(ghzuuemkdt) = vtknuxsuhf ilytclecke (jasadbvonv ) View more | |||||||
Phase 2 | 330 | Rademikibart300 mg Q4W (In patients that achieved IGA 0/1 or EASI-75 at Week 16) | wvwjgsdbub(drtgcejelm) = todhapxlxm xxmkayqufk (hhdssghodw ) View more | Positive | 21 Nov 2023 | ||
Rademikibart 300 mg Q2W (In patients that achieved IGA 0/1 or EASI-75 at Week 16) | wvwjgsdbub(drtgcejelm) = moefuyjvad xxmkayqufk (hhdssghodw ) View more | ||||||
Phase 2 | 226 | placebo | jhwdegjcaz(hjgfszdjlj) = ojustrruwb cvbzysqzig (icmvasabpv, 4.638) View more | - | 01 Aug 2023 | ||
Phase 2 | 255 | mhdcwwpawn(ewjxzwvfix) = sqfpvsviic wklovmcvpt (oqawymqrnh ) View more | - | 03 Jul 2023 | |||
Placebo | mhdcwwpawn(ewjxzwvfix) = ijnmqcaeiq wklovmcvpt (oqawymqrnh ) View more | ||||||
Phase 2 | 255 | kcbromvtfo(tuelxvausu) = vhyfkmwvzl xibitgppxw (ccbulasyvu ) View more | - | 03 Jul 2023 | |||
Placebo | kcbromvtfo(tuelxvausu) = bhzcbwgjcm xibitgppxw (ccbulasyvu ) View more | ||||||
Phase 2 | 255 | dxbzzlcump(tbjoilcrdb) = azwuruiolp iypbgxfpxb (mdygmknkqg ) | Positive | 03 Jul 2023 | |||
Placebo | dxbzzlcump(tbjoilcrdb) = dgzkcjmcta iypbgxfpxb (mdygmknkqg ) |